Research Projects

While Alzheimer’s Disease (AD) is a global pandemic, it has been estimated that a five-year delay in the disease onset could reduce the disease prevalence – and its costs – by up to 33% over the next decades, representing potential savings over €100bn in EU alone. However, there are still significant roadblocks ahead as current drugs do not untap...

The project will build an application to help informal caregivers of demented people (typically a spouse or an adult child) understand and aid their demented relatives and help them manage their new life situation.

Alzheimer’s disease (AD) is central to the rapidly growing and crushing ageing challenge that threatens to economically undermine today’s health care system. AD prevalence will grow to over 100m cases in 2050. AD is incurable, but can be prevented. Detecting pre-symptomatic signs of AD in at-risk groups and intervening early may be the only viable...

Neurodegenerative disorders, represented mostly by Alzheimer's disease (AD) and Parkinson's disease (PD), are characterised by progressive neuronal impairment and death. In spite of the brain's known capacity for regeneration, lost neurons generally cannot be replaced. Therefore, drugs aimed at inhibiting neurodegenerative processes are likely to...

Alzheimer’s disease (AD) affects more than 7 million people in Europe and this figure is expected to double every 20 years. Despite intensive efforts, no disease-modifying treatments or preventive strategies are available. The lack of specific, sensitive and minimally invasive diagnostics to identify people with early-stage AD to be included in...

The calcium sensing receptor (CaSR) is a class C Gprotein-coupled receptor that plays a pivotal role in systemic calcium metabolism by regulating parathyroid hormone secretion and urinary Ca excretion. Abnormal CaSR function is implicated in calciotropic disorders, and in non-calciotropic disorders such as Alzheimer’s disease (AD), cardiovascular...

CHANCES aims at combining and integrating on-going cohort studies in order to produce evidence on ageing-related health characteristics and determinants in Europe, and their socio-economic implications. 15 cohorts participate, covering populations from 18 EU Member States, 4 associate countries, and 3 additional countries. The combination of these...

Alzheimer’s disease (AD) imposes an enormous personal burden on patients and caregivers, as well as a tremendous socio-economic impact on society. However, there is a paucity of pharmaceutical or interventional strategies that have a proven impact on the incidence or progression of AD. One reason is that most models are based on familial (early...

The goal of BATCure is to advance the development of new therapeutic options for a group of rare lysosomal diseases - neuronal ceroid lipofuscinoses (NCL) or Batten disease. There are > thousand affected across Europe, with a combined incidence of c.1:100 000. The NCLs are devastating and debilitating genetic disorders that mainly affect children...

Neurodegenerative disorders such as, Alzheimer’s disease (AD), Mild Cognitive Impairment (MCI), stroke, Traumatic Brain Injury (TBI) and chronic stress create a major economic burden to society and a substantial reduction in quality of life for patients and families. The development of neuroregenerative therapies is notoriously difficult and...

Induced pluripotent stem cells (iPSC) are the cornerstone of many regenerative medicine projects, and offer researchers a powerful new approach to model and study a range of diseases. The European Bank for Induced Pluripotent Stem Cells (EBiSC) was established to provide researchers across academia and the pharmaceutical industry with disease...